Helping clients better compete in an evolving health market and improve cost-efficiency and profitability
The US health industry has often lagged other industries when it comes to modernizing. Once thought to operate outside the greater US economy, the industry—with its byzantine payment system, complicated regulatory barriers and reliance on face-to-face interactions—is being disrupted. Finally, there’s robust evidence that what PwC calls the New Health Economy is kicking into gear.
From President Trump's tax plan to healthcare reform—we break down developments from Washington and what companies in our industry need to do to anticipate and prepare for legislative change.
Karen C. Young
US Pharmaceutical and Life Sciences Leader, PwC US
Global Pharmaceutical and Life Sciences Leader, PwC US
US Health Industries Tax Leader, PwC US
Global Pharmaceutical and Life Sciences Advisory Leader, PwC US
Principal, Strategy&, PwC US
US Pharmaceutical and Life Sciences Deals Leader, PwC US
US Pharmaceutical & Life Sciences Assurance Leader, PwC US
US Pharmaceutical and Life Sciences Risk Assurance Leader, PwC US